The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...

Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing drug, after concerns it may have accelerated ageing rather than reversed it.

So far, 170 dogs are participating in the trial. With a new $7 million federal grant, researchers hope to expand the study to ...

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China ...